Search Results
Aug 31, 2026, 09:00 ET Ecoer Marks 10 Years of Innovation with 2026 HVAC All-Star Recognition
Ecoer.com.About ACHR NEWSEstablished in 1926, The Air Conditioning, Heating and Refrigeration NEWS (ACHR NEWS) is a leading publication serving HVACR contractors and industry professionals. Its HVAC All-Star
More news about: Ecoer
Aug 26, 2026, 07:15 ET Bluon brings back best-in-class Live Tech Support for HVAC-R field technicians
The relaunch lands in the middle of a widening labor gap. According to ACHR News, the HVAC industry is short roughly 110,000 technicians and doubling to 225,000 by 2030. With about 25,000 experienced technicians leaving the
More news about: Bluon
Aug 24, 2026, 19:12 ET FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients
in the United States in April 2025 for the treatment of gMG in adult and pediatric patients 12 years of age and older who are acetylcholine receptor (AChR) or muscle-specific kinase (MuSK) antibody positive.5Johnson & Johnson is committed to helping patients access our treatments.
More news about: Johnson & Johnson
Aug 10, 2026, 08:00 ET Archer to Shape Physical AI Future of Aerospace and Defense with Acquisition of Boeing's Wisk Aero, Insitu and SkyGrid Subsidiaries; Boeing to Invest in Archer and Collaborate
VALLEY, Calif., Aug. 10, 2026 /PRNewswire/ -- The Boeing Company (NYSE: BA) and Archer Aviation Inc. (NYSE: ACHR) today announced the companies have signed definitive agreements in which Archer will acquire Boeing's Wisk Aero, SkyGrid and Insitu subsidiaries. The
More news about: Boeing
Aug 06, 2026, 16:01 ET HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE
VYVGART® Hytrulo with ENHANZE® for the treatment of adult patients with generalized myasthenia gravis including all serotypes – anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and triple seronegative.In May 2026, Halozyme and GSK plc ("GSK") entered into a
More news about: Halozyme Therapeutics, Inc.
Jul 28, 2026, 08:08 ET Lennox Earns Two 2026 HVAC All-Star Awards for Innovation and Industry Leadership
DALLAS, July 28, 2026 /PRNewswire/ -- Air Conditioning, Heating & Refrigeration (ACHR) News has recognized Lennox for excellence in innovation and industry leadership with two 2026 HVAC All-Star Awards. Lennox Commercial HVAC
More news about: Lennox International Inc.
Jul 28, 2026, 07:03 ET Lemon Seed Marketing's 'From the Yellow Chair' wins ACHR News HVAC All-Star Award
The ACHR News' HVAC All-Star Awards 2026.
More news about: Lemon Seed Marketing
Jul 27, 2026, 08:00 ET Cognizin® Citicoline Shows Promise for Neuromuscular Health in New Preclinical Research
expression analysis and immunofluorescence imaging, researchers assessed key markers involved in NMJ development, including acetylcholine receptor (AChR) clustering, a critical step in the formation of a functional NMJ."Consumers and manufacturers alike are increasingly demanding more from cognitive
More news about: Kyowa Hakko U.S.A
Jun 26, 2026, 12:35 ET Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis
pediatric patients (12 years of age and older) with anti-AChR or anti-MuSK antibody positive gMG by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).10,11Editor's Notes:a. Anti-AChR+= anti-acetylcholine receptor positive antibody.b.
More news about: Johnson & Johnson
Jun 11, 2026, 02:03 ET IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies
the treatment of generalized myasthenia gravis (gMG) in adults and pediatric patients 12 years of age and older who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.8Nipocalimab is being investigated across three key segments in
More news about: Johnson & Johnson
Jun 03, 2026, 09:00 ET AMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026
anti-aquaporin-4 (AQP4) antibody positive neuromyelitis optica spectrum disorder (NMOSD); Immunoglobulin G4-related disease (IgG4-RD); anti-acetylcholine receptor (AChR) or anti-muscle specific tyrosine kinase (MuSK) antibody positive (Ab+) generalized myasthenia gravis (gMG).UPLIZNA U.S. IMPORTANT SAFETY
More news about: Amgen
Jun 02, 2026, 16:45 ET Mês da Miastenia Gravis comemora recente aprovação da primeira terapia subcutânea com foco na melhora funcional e na qualidade de vida do paciente(1)
para os anticorpos anti-MuSK e/ou anti-AChR5. O diferencial do novo medicamento está em seu mecanismo de ação inovador. Na miastenia gravis generalizada, o organismo passa a produzir autoanticorpos patogênicos — como os anti-AChR e anti-MuSK5 —
More news about: UCB Biopharma
May 18, 2026, 12:07 ET Hotter Summers and Rising Energy Costs Drive Demand for Next-Generation Inverter Heat Pumps
industry, is helping homeowners smoothly transition to modern, energy-efficient heat pump systems with its growing EVOX and multi-zone lineup. Recognized by ACHR News as a rising brand in the North American heat pump market, Midea's EVOX lineup has earned coverage in over 100 trade articles in 2025 alone. Midea
More news about: Midea RAC
May 11, 2026, 16:01 ET HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE
VYVGART® Hytrulo with ENHANZE® for the treatment of adult patients with generalized myasthenia gravis ("gMG") including all serotypes – anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and triple seronegative.In May 2026, Halozyme and GSK plc ("GSK") entered into a
More news about: Halozyme Therapeutics, Inc.
Apr 30, 2026, 19:02 ET /C O R R E C T I O N -- Amgen/
UPLIZNA as an add-on to standard therapy for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle specific tyrosine kinase (MuSK) antibody positive.Phase 3 studies of UPLIZNA in patients with autoimmune hepatitis and in patients
More news about: Amgen
Apr 27, 2026, 08:03 ET FDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA)
the treatment of generalized myasthenia gravis (gMG) in adults and pediatric patients 12 years of age and older who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.10Nipocalimab is being investigated across three key segments in
More news about: Johnson & Johnson
Apr 22, 2026, 08:05 ET IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)
weeks of follow-up, IMAAVY delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients including anti-AChR+ and anti-MuSK+Patients achieving sustained minimal symptom expression (MSE) experienced greater improvements in quality of life than
More news about: Johnson & Johnson
Apr 13, 2026, 07:00 ET UCB announces new clinical data from its generalized myasthenia gravis (gMG) portfolio at the 2026 American Academy of Neurology (AAN) meeting
/PRNewswire/ -- UCB, a global biopharmaceutical company, today announced data from two clinical studies assessing ZLP-AI in adult patients who are anti-AChR antibody positivegMG as well as in healthy volunteers. The studies evaluated the effectiveness of a ZLP- AI as a potential new alternative administration
More news about: UCB
Mar 25, 2026, 09:00 ET Beyond Legacy Defense: The New Blueprint for Scalable Aerospace Growth
suppliers[2]. This environment was practically built for a specific tier of innovators: Starfighters Space (NYSE-A: FJET), Archer Aviation (NYSE: ACHR), AeroVironment (NASDAQ: AVAV), Velo3D (NASDAQ: VELO), and AgEagle Aerial Systems (dba EagleNXT) (NYSE-A: UAVS) represent
More news about: USA News Group
Feb 24, 2026, 16:03 ET Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)
2025 for the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients 12 years of age and older who are acetylcholine receptor (AChR) or muscle-specific kinase (MuSK) antibody positive.6The full results of the ENERGY trial are forthcoming.
More news about: Johnson & Johnson
Feb 20, 2026, 09:15 ET AI Takes Flight: Five Companies Advancing Defense and Aerospace Intelligence
operating at the intersection of aerospace, AI, and national security are Starfighters Space (NYSE American: FJET), Archer Aviation (NYSE: ACHR), AeroVironment (NASDAQ: AVAV), Redwire (NYSE: RDW), and V2X (NYSE: VVX).
More news about: USA News Group
Feb 13, 2026, 16:53 ET EUROPÄISCHE KOMMISSION GENEHMIGT UPLIZNA® VON AMGEN FÜR GENERALISIERTE MYASTHENIA GRAVIS
Studienpopulation, die Veränderung des MG-ADL-Scores gegenüber dem Ausgangswert in Woche 26 für die AChR+-Kohorte und separat für die MuSK+-Kohorte sowie die Veränderung des QMG-Scores gegenüber dem Ausgangswert in Woche 26 für die AChR+-Kohorte und separat für die MuSK+-Kohorte.5 MINT beinhaltet außerdem einen
More news about: Amgen
Feb 13, 2026, 14:41 ET EURÓPSKA KOMISIA SCHVÁLILA LIEK UPLIZNA® OD SPOLOČNOSTI AMGEN NA LIEČBU GENERALIZOVANEJ MYASTÉNIE GRAVIS
na protilátky anti-AChR a anti-MuSK prináša liek UPLIZNA nový, prvotriedny prístup k liečbe tohto komplexného ochorenia."Schválenie EK podporujú údaje zo skúšania Myasthenia Gravis Inebilizumab (MINT), najväčšieho biologického skúšania fázy 3, ktoré zahŕňa pacientov s AChR+ aj MuSK+ a je prvým,
More news about: Amgen
Feb 13, 2026, 11:47 ET ЕВРОПЕЙСКАЯ КОМИССИЯ ОДОБРИЛА ПРЕПАРАТ AMGEN UPLIZNA ® ДЛЯ ЛЕЧЕНИЯ ГЕНЕРАЛИЗОВАННОЙ МИАСТЕНИИ
объединенной исследуемой популяции; изменение от исходного уровня по шкале MG-ADL на неделе 26 для когорты AChR+ и отдельно для когорты MuSK+; и изменение от исходного уровня по шкале QMG на неделе 26 для когорты AChR+ и отдельно для когорты MuSK+.5 MINT также включает необязательный трехлетний период
More news about: Amgen
Feb 13, 2026, 11:41 ET EVROPSKÁ KOMISE SCHVÁLILA PŘÍPRAVEK UPLIZNA® SPOLEČNOSTI AMGEN PRO GENERALIZOVANOU MYASTENII GRAVIS
pozitivními gMG protilátkami proti AChR a MuSK přináší UPLIZNA nový prvotřídní přístup k léčbě tohoto komplexního onemocnění."Schválení EK je podpořeno údaji ze studie Myasthenia Gravis Inebilizumab Trial (MINT), největší biologické studie fáze 3, která zahrnovala pacienty s AChR+ i MuSK+ a jako první úspěšně
More news about: Amgen